Gliadel® (carmustine implant) is a prescription chemotherapy medicine used to treat certain types of brain tumors called malignant glioma and glioblastoma multiforme. It belongs to a group of medicines known as nitrosoureas.
In clinical studies examining the efficacy of Gliadel, the drug was shown to improve survival in people with newly diagnosed cancerous brain tumors. One study showed that people who received Gliadel had a median survival of 13.8 months, compared with a median survival of 11.6 months in people who were given a placebo implant (an implant that did not contain any active ingredients).
(Click Gliadel to learn more about this drug's safety and efficacy, as well as dosing guidelines, potential side effects, and more.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Gliadel [package insert]. Woodcliff Lake, NJ: Eisai, Inc.;2010 April.
Gliadel Web site. Available at: http://www.gliadel.com/. Accessed August 4, 2012.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed August 4, 2012.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 8th ed. Philadelphia (PA): Lippincott Williams & Wilkins;2008.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click